reports
Pliant Therapeutics Announces Interim Data from PLN-101095 in Patients...
Pliant Therapeutics Announces Interim Data from PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors One complete response and three partial responses observed in heavily pretreated ICI-secondary refractory patients in high dose cohorts Deep and durable ongoing responses with median time on treatment of 15 months Company to accelerate development of PLN-101095 with initiation of a Phase 1b expansion trial in 2026 Strong cash position supports planned operations through 2028 SOUTH SAN FRANCISCO, Calif., Dec. 04, 2025 (GLOBE NEWSWIRE) -- Pliant Thera...
Pliant Therapeutics to Participate in the Piper Sandler Healthcare Con...
Pliant Therapeutics to Participate in the Piper Sandler Healthcare Conference SOUTH SAN FRANCISCO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company focused on the discovery and development of integrin-based therapeutics, today announced its participation in the Piper Sandler 37th Annual Healthcare Conference to be held December 2 – 4, 2025.Bernard Coulie, M.D., Ph.D., President and Chief Executive Officer, Keith Cummings, M.D., Chief Financial Officer and Éric Lefebvre, M.D., Chief Medical Officer, will participate in a fir...
Pliant Therapeutics Provides Corporate Update and Reports Third Quarte...
Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results Oncology program advancing with data expected in the fourth quarter 2025 BEACON-IPF close out activities to be completed in the fourth quarter 2025 SOUTH SAN FRANCISCO, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company focused on the discovery and development of integrin-based therapeutics, today provided a corporate update and reported third quarter 2025 financial results. “During the third quarter, our team continued t...
Pliant Therapeutics Provides Corporate Update and Reports Second Quart...
Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results BEACON-IPF close out activities continue Previously announced workforce and operational realignment largely complete Phase 1 oncology trial on track to deliver additional data by the end of the year SOUTH SAN FRANCISCO, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company and leader in integrin-based drug development, today provided a corporate update and reported second quarter 2025 financial results. “While our activiti...
Pliant Therapeutics Provides Update on BEACON-IPF
Pliant Therapeutics Provides Update on BEACON-IPF Bexotegrast development in IPF discontinued Clinical oncology program and early-stage programs continue Recent workforce and operational changes align with next steps SOUTH SAN FRANCISCO, Calif., June 27, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that following the review of data from the recently terminated BEACON-IPF Phase 2b/3 clinical trial, the Company has discontinued development of bexotegrast in idiopathic pulmonary fibrosis (IPF). BEACON-IPF Trial Update BEACON-IPF was a randomized, do...
Pliant Therapeutics Presents Clinical and Preclinical Data at the Amer...
Pliant Therapeutics Presents Clinical and Preclinical Data at the American Thoracic Society International Conference SOUTH SAN FRANCISCO, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that the Company led oral and poster presentations of clinical and preclinical data this week as part of the American Thoracic Society (ATS) 2025 International Conference, held from May 16-21, 2025. In a featured oral presentation, Johanna Schaub, Ph.D., Director of Translational Sciences at Pliant Therapeutics, discussed an evaluation of the antifibrotic ...
Pliant Therapeutics Provides Corporate Update and Reports First Quarte...
Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results Activities supporting the close out of BEACON-IPF continue; topline data expected in the second quarter of 2025 Recently announced strategic realignment of workforce and operations will extend cash runway to support execution of late-stage clinical trials SOUTH SAN FRANCISCO, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic dis...
Pliant Therapeutics Announces Strategic Realignment of Workforce and O...
Pliant Therapeutics Announces Strategic Realignment of Workforce and Operations - Implementation of cost reduction initiatives to position Pliant for execution of late-stage clinical trials - Pliant will reduce its current workforce by approximately 45% - Closing activities for BEACON-IPF trial ongoing; topline data expected in the second quarter of 2025 SOUTH SAN FRANCISCO, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced a strategic restructuring of its workforce and other cost saving actions to extend the cash runway to support exe...
Pliant Therapeutics Announces Upcoming Presentations at the 2025 Ameri...
Pliant Therapeutics Announces Upcoming Presentations at the 2025 American Thoracic Society International Conference SOUTH SAN FRANCISCO, Calif., April 07, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that the Company will present three scientific posters at the upcoming 2025 American Thoracic Society (ATS) International Conference, taking place in San Francisco, California from May 16-21, 2025. The following abstracts are posted on ATS 2025’s online itinerary planner for registered users. Pliant was selected for a featured oral presentation as part o...
Pliant Therapeutics Announces Interim Phase 1 Data for PLN-101095 in P...
Pliant Therapeutics Announces Interim Phase 1 Data for PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors Antitumor activity observed with confirmed partial responses in 50% of patientsat highest dose tested to date, across multiple tumor types PLN-101095 was generally well tolerated across all doses SOUTH SAN FRANCISCO, Calif., March 17, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced data from the first three of five potential cohorts of its ongoing Phase 1 dose escalation clinical trial evaluating PLN-101095, an ...
Pliant Therapeutics Adopts Limited Duration Stockholder Rights Agreeme...
Pliant Therapeutics Adopts Limited Duration Stockholder Rights Agreement SOUTH SAN FRANCISCO, Calif., March 13, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that its Board of Directors has unanimously adopted a limited duration stockholder rights agreement (the “Rights Agreement”) to protect stockholder interests. The Board resolved to adopt the Rights Agreement in response to recent accumulations of the Company’s common stock. The Rights Agreement is intended to reduce the likelihood that any entity, person or group is able to gain control of Pliant ...
CytoSorbents Postpones Earnings Release to Allow More Time to Complete...
CytoSorbents Postpones Earnings Release to Allow More Time to Complete Annual Audit Following the Passing of Corporate Controller The Company reaffirms previously provided preliminary financial results for the quarter and full year ended December 31, 2024, and continues to expect regulatory decisions on DrugSorb™-ATR marketing applications in 2025 PRINCETON, N.J., March 04, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today announced that it is postponing its pr...
Pliant Therapeutics Provides Corporate Update and Reports Fourth Quart...
Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2024 Financial Results Discontinuation of BEACON-IPF following DSMB and outside expert panel recommendation SOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment of fibrotic diseases, today provided a corporate update and reported fourth quarter 2024 financial results. Fourth Quarter and Recent Highlights Bexotegrast Highlights BEACON-IPF di...
Pliant Therapeutics Provides Update on BEACON-IPF, a Phase 2b/3 Trial ...
Pliant Therapeutics Provides Update on BEACON-IPF, a Phase 2b/3 Trial in Patients with Idiopathic Pulmonary Fibrosis SOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that following a prespecified data review and recommendation by the trial’s independent Data Safety Monitoring Board (DSMB), as well as a secondary review and recommendation by an outside expert panel, Pliant has discontinued the BEACON-IPF Phase 2b trial evaluating bexotegrast in patients with idiopathic pulmonary fibrosis (IPF). While an imbalance in un...
CytoSorbents to Report Fourth Quarter and Full Year 2024 Financial Res...
CytoSorbents to Report Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights PRINCETON, N.J., Feb. 26, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, will report fourth quarter and full year 2024 financial results and recent business highlights after the market close on Thursday, March 6, 2025. CytoSorbents’ management will host a live conference call, presentation webcast, and a question-and-answer session starting at 4:30 PM ET the sa...
CytoSorbents Further Strengthens Balance Sheet with Exercise of Previo...
CytoSorbents Further Strengthens Balance Sheet with Exercise of Previously Announced Series A Right Warrants 1,417,208 Series A Right Warrants Exercised at $1.13 Per Share, Providing $1.6 Million in Aggregate Gross Proceeds PRINCETON, N.J., Feb. 25, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announced today the Company received aggregate gross proceeds of $1.6 million from the exercise of 1,417,208 Series A Right Warrants at $1.13 per warrant upon their expira...
Pliant Therapeutics Announces Next Steps Following DSMB Recommendation...
Pliant Therapeutics Announces Next Steps Following DSMB Recommendation on BEACON-IPF, a Phase 2b/3 Trial in Patients with Idiopathic Pulmonary Fibrosis Pliant has initiated assembly of outside panel of world-renowned experts to review BEACON-IPF trial data SOUTH SAN FRANCISCO, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that, per the charter of the trial’s independent Data Safety Monitoring Board (DSMB), the Company has initiated the assembly of an outside expert panel to review unblinded data from the ongoing BEACON-IPF Phase 2b tr...
- Jonathan Moreland
XNCR XENCOR INC.
RLI RLI CORP.
PBF PBF ENERGY INC. CLASS A
ORRF ORRSTOWN FINANCIAL SERVICES INC.
NEOG NEOGEN CORPORATION
MKL MARKEL CORPORATION
LAKE LAKELAND INDUSTRIES INC.
JBLU JETBLUE AIRWAYS CORPORATION
EL ESTEE LAUDER COMPANIES INC. CLASS A
CTSO CYTOSORBENTS
BUSE FIRST BUSEY CORPORATION
BAH BOOZ ALLEN HAMILTON HOLDING CORPORATION CLASS A
CBFV CB FINANCIAL SERVICES INC.
MUR MURPHY OIL CORPORATION
OLN OLIN CORPORATION
WVE WAVE LIFE SCIENCES
OVLY OAK VALLEY BANCORP
FLWS 1-800-FLOWERS.COM CL A
KALV KALVISTA PHARMACEUTICALS
ANAB ANAPTYSBIO INC.
MHI PIONEER MUNICIPAL HIGH INCOME TRUST
MPB MID PENN BANCORP INC.
CIK CREDIT SUISSE ASSET MANAGEMENT INCOME FUND INC.
COGT COGINT
NWFL INC.
FRAF NORWOOD FINANCIAL CORP.
ETST FRANKLIN FINANCIAL SERVICES CO.
LOOP EARTH SCIENCE TECH
ANIX LOOP INDUSTRIES
MFON ANIXA BIOSCIENCES
PNTG MOBIVITY HOLDINGS CORP.
ZYME PENNANT GROUP
PLCE ZYMEWORKS INC.
ALLY THE CHILDREN'S PLACE RETAIL STORES
IMNM INC.
CTOS GMAC LLC
IBRX IMMUNOME
BHRB CUSTOM TRUCK ONE SOURCE
VGAS INC.
TLSI IMMUNITYBIO INC
TKO BURKE & HERBERT BANK & TR/VA
PCSA VERDE CLEAN FUELS INC
PROP TRISALUS LIFE SCIENCES INC
MIO TKO GROUP HOLDINGS
MXF INC.
SUNS PROCESSA PHARMACEUTICALS INC
BATRK PRAIRIE OPERATING CO.
MYCB PIONEER MUN HIGH INCOME OPPORTUNITIES FD INC
THE MEXICO FUND
INC.
SUNRISE REALTY TRUST
LIBERTY MEDIA CORPORATION
MY CITY BUILDERS
INC.
Pliant Therapeutics Provides Update on BEACON-IPF, a Phase 2b/3 Trial ...
Pliant Therapeutics Provides Update on BEACON-IPF, a Phase 2b/3 Trial in Patients with Idiopathic Pulmonary Fibrosis Following DSMB recommendation, the Company has voluntarily paused enrollment and dosing in the BEACON-IPF Phase 2b trial and will monitor current patients while data is reviewed SOUTH SAN FRANCISCO, Calif., Feb. 07, 2025 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced that following a prespecified data review and recommendations by the trial’s independent Data Safety Monitoring Board (DSMB), the Company has voluntarily paused enrollment and dos...
- Jonathan Moreland
RLI RLI CORP.
NEOG NEOGEN CORPORATION
LNDC LANDEC CORP.
LAKE LAKELAND INDUSTRIES INC.
CTSO CYTOSORBENTS
ASA ASA
WVE WAVE LIFE SCIENCES
OVLY OAK VALLEY BANCORP
FLWS 1-800-FLOWERS.COM CL A
FBK FB FINANCIAL CORPORATION
NQP NUVEEN PENNSYLVANIA INVESTMENT QUALITY MUNICIPAL FUND INC.
LW LAMB WESTON HOLDINGS INC.
ANAB ANAPTYSBIO INC.
MAV PIONEER MUNICIPAL HIGH INCOME ADVANTAGE TRUST
MHI PIONEER MUNICIPAL HIGH INCOME TRUST
ESQ ESQUIRE FINANCIAL HOLDINGS
MPB MID PENN BANCORP INC.
CIK CREDIT SUISSE ASSET MANAGEMENT INCOME FUND INC.
COGT COGINT
ETST INC.
LOOP EARTH SCIENCE TECH
FUND LOOP INDUSTRIES
ANIX ROYCE FOCUS TRUST
LBSRD INC.
ETON ANIXA BIOSCIENCES
GRX LIBERTY STAR URANIUM & METALS
MFON ETON PHARMACEUTICALS
PNTG THE GABELLI HEALTHCARE & WELLNESSRX TRUST
ZYME MOBIVITY HOLDINGS CORP.
ALLY PENNANT GROUP
ENX ZYMEWORKS INC.
IBRX GMAC LLC
ACXP EATON VANCE NEW YORK MUNICIPAL BOND FUND
CVI IMMUNITYBIO INC
TLSI ACURX PHARMACEUTICALS INC
PCSA CVR ENERGY
PROP INC.
AVDL TRISALUS LIFE SCIENCES INC
MIO PROCESSA PHARMACEUTICALS INC
MXF PRAIRIE OPERATING CO.
SUNS AVADEL PHARMACEUTICALS PUBLIC LIMITED COMPANY
TXO PIONEER MUN HIGH INCOME OPPORTUNITIES FD INC
AMST THE MEXICO FUND
WHLM INC.
IBIO SUNRISE REALTY TRUST
SDHY MORNINGSTAR PARTNERS
BATRK L.P.
MYCB AMESITE INC.
WILHELMINA INTERNATIONAL INC
IBIO INC.
PGIM SHORT DURATION HIGH YIELD OPPORTUNITIES FUND
LIBERTY MEDIA CORPORATION
MY CITY BUILDERS
INC.
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.